Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management

International Journal of Hematology

Volumn 82, Issue 4, 2005, Pages 343-346

  Ikuta, Katsuya ^a   Torimoto, Yoshihiro ^a   Jimbo, Junko ^a   Inamura, Junki ^a   Shindo, Motohiro ^a   Sato, Kazuya ^a   Tokusashi, Yoshihiko ^a   Miyokawa, Naoyuki ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Allergic mechanism; Chronic myeloid leukemia (CML); Hepatic injury; Imatinib mesylate; Prednisolone

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; NEOMINOPHAGEN C; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EDEMA; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER INJURY; NAUSEA; PROGNOSIS; RASH;

ANTINEOPLASTIC AGENTS; BIOPSY; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LIVER; LIVER DISEASES; MIDDLE AGED; PIPERAZINES; PREDNISOLONE; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 33644697678     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05034     Document Type: Article

References (14)

1. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol. 2002;20:325-334.
2. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol. 2001;5:9-18.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
4. Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348:1048-1050.
5. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001;98:2039-2042.
6. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
7. Burton C, Azzi A, Kerridge I. Adverse events after imatinib mesylate therapy. N Engl J Med. 2002;346:713.
8. Elliott MA, Mesa RA, Tefferi A. Adverse effects after imatinib mesylate therapy. N Engl J Med. 2002;346:712-713.
9. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160-2161.
10. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon F-X. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003;17:978-979.
11. Lin NU, Sarantopoulos S, Stone JR, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455-3456.
12. Kikuchi S, Muroi K, Takahashi S. et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma. 2004;45:2349-2351.
13. Tanaka H, Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem Biophys Res Commun. 1992;188:942-948.
14. Tanaka H, Makino Y, Miura T, et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. J Immunol. 1996;156:1601-1608.